Mar 20, 2025 8:00am EDT RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
Mar 19, 2025 8:00am EDT RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
Feb 26, 2025 8:00am EST RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
Feb 13, 2025 8:00am EST RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
Feb 11, 2025 7:00am EST RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Feb 06, 2025 8:49pm EST RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
Jan 27, 2025 8:00am EST RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
Jan 08, 2025 8:00am EST RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
Dec 30, 2024 8:00am EST RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
